News & Resources

KOL Engagement in 2022 – A Reality Check

When key opinion leader (KOL) outreach activities moved online early in the COVID-19 pandemic, many saw the shift as temporary, assuming we would return to business as usual within a year.

Two years later, virtual interactions are the new normal between KOLs and pharmaceutical teams, and at least for the time being, the in-person ways that pharma once engaged KOLs don’t apply. Now is the time to take a realistic look at a system profoundly altered by the pandemic and determine how to optimize outreach in that context.

The preference for virtual interactions between pharma and expert counsel is unlikely to budge anytime soon, not only due to safety guidelines, but also the time-saving convenience of virtual meetings, which allow for more flexibility and eliminate expenses and time lost to travel.

Dressing Up Virtual Communications
KOLs will always be an essential resource to pharma for research, product development, and product support, but building strong relationships through online interaction is more difficult than in-person. Emails, Slack messages, and virtual meetings don’t have the vitality of face-to-face conversations.

One way to enliven virtual interactions is to communicate your message in narrative form. Rather than inundate KOLs with data and technical jargon, tell the story of your company’s projects and products with relatable emotion. This is meant to be a mutually beneficial partnership, so create a welcoming space that your contacts will want to engage with.

You can also enliven virtual meetings through a wide range of technological features. Consider integrating infographics, podcasts, video abstracts, polling tools, microsites, and social media into outreach. There are many ways to strengthen engagement that your employees may already have the skills to implement.

Planning
Creating a focused and streamlined plan is important with any KOL outreach, but particularly within 2022’s rapidly advancing oncology market. This exponential growth is primarily driven by 2 factors.

First is the large number of older adults in the population. Estimates predict approximately 70% of cancers will be in adults 65 and older by the year 2030. Second, immunology, combination therapies, and the success of increasingly personalized treatment plans have opened up exciting new avenues in the pharmaceutical industry. The global oncology pharmaceutical market is expected to increase from over $177 billion in 2021 to $313.7 billion by 2026.

In this time of overwhelming growth, relationships with scientific experts are becoming increasingly important but also more challenging. Today’s oncology leaders tend to be quite specialized, requiring pharma teams to carefully target the KOLs who can help products succeed.

Complex and time-consuming analysis and mapping of customer data are needed to identify ideal KOLs and plan an effective outreach approach, so partnering with the right agency is crucial to ensure the process is cost-effective. Even successful in-house information mapping can lead to more than 1 pharma team unknowingly targeting the same expert, which does not make the best impression. Contracting with an outside agency that has a large enough platform to keep a company’s micro and macro concerns in the picture simultaneously can avoid such mistakes.

Just as medical research is becoming increasingly global, so must pharma companies expand their business intelligence for more organization-wide KOL identification and engagement. A partnership with the right specialized agency gives companies the power of centralized data platforms that consolidate experts and activities into a single source, significantly reducing waste and inefficiency and allowing KOL outreach to be coordinated so that experts are strategically utilized for the projects that need their guidance most.

Communicating Quality
At a time when healthcare providers have shifted to patient-centered care that emphasizes value over volume, it is crucial for pharma to always transmit a message of quality.

KOL engagement in 2022 needs to clearly communicate how product and brand quality connects to the needs of your targeted KOL. The sincerity of your company narrative and your passion for the endeavor or product at hand must be felt. Your technology must function well as you communicate an engaging message that consistently supports a depiction of mutual benefit. All these factors combined are what will cause a thought leader to feel confident enough in your future to want to take part in it.

As you prepare your outreach strategy, consider what issues your KOL may be facing and develop solutions that you have the resources to implement. Assess their priorities and goals and demonstrate how their objectives align with your own. Ideally, you should already be targeting KOLs on the basis of how their goals dovetail with yours. One perfect-fit KOL is better than 10 connections that don’t quite hit the mark. Create opportunities for collaborations such as advisory board positions, sponsorships, and publishing opportunities. Consider how you can create partnerships between various KOLs you are working with.

Most importantly, to sustain a lasting, value-rich relationship, encourage open and honest communication with your KOLs. Welcome all kinds of feedback and consider it thoughtfully. After all, you have connected with your KOLs for their insights.

Be Gracious
In 2022 more than ever, professional courtesy is crucial. The pandemic has stretched most people in the healthcare industry to their limits. With ICUs filled with COVID patients, surgeons have had to cancel procedures that suffering patients need for mobility issues or chronic pain. Doctors at already-understaffed hospitals are traumatized by devastating working conditions and the grief and stress brought on by having to turn away or neglect patients in need. Under conditions like this, the kind of thoughtlessness someone might have overlooked a few years ago could ruin a relationship today.

Most KOLs consider time management the greatest benefit of virtual engagement, but they can only enjoy that benefit if you meet their expectations. Representatives need to log in for meetings at the agreed-upon time, fully prepared to proceed. Be thorough but wrap up meetings promptly. Extending conversation past the set endpoint disrespects your contact’s time. Be personable without being overly personal. It is best to allow your KOLs to set the tone and pace for the social side of your interactions and follow their lead when it comes to professional boundaries.

Agency Partners
KOL engagement in the current climate has a unique set of challenges. Partnering with a trusted organization that provides immediate virtual access to KOLs can give your company a considerable advantage. Aptitude Health’s digital platforms encourage collaboration, creating connections between clinical experts, life science companies, and community-based physicians with a robust virtual platform that makes communicating simple. Our hematology-oncology specialists will provide you with expert advice and feedback. Learn more about our services today.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.